



Queensland Health

Enquiries to: Bill Loveday  
Director  
Monitored Medicines and  
Compliance Unit  
Telephone: [REDACTED]  
File Ref: C-ECTF-25/19585

Dr Nick Yim  
President – Australian Medical Association Queensland

Professor Brett Emmerson  
Chair, Queensland Branch, The Royal Australian and New Zealand College of  
Psychiatrists

Mr Chris Owen  
President, Pharmacy Guild of Australia Queensland

Dr Cath Hester  
Chair, Royal Australian College of General Practitioners Queensland

Email: [REDACTED]

Dear Dr Yim, Professor Emmerson, Mr Owen and Dr Hester,

Thank you for your letter of 10 September 2025 to the Minister for Health and Ambulance Services providing examples of medicinal cannabis adverse outcomes to support the Minister's discussion of medicinal cannabis reform at the Health Ministers' Meeting of 12 September 2025. Thank you for this information on these matters and this has been noted by the Minister's office.

The Minister has forwarded your correspondence to me to respond to, as the Office of the Chief Medical Officer, Health Workforce Division administers regulatory compliance matters related to medicinal cannabis medicines under the Medicines and Poisons Act 2019.

I would also like to take this opportunity to remind you that if your members have concerns regarding the patient's use of monitored medicines, such as Schedule 8 – medicinal cannabis medicines, they can report this to Queensland Health by completing an online General Report, which will be assessed and investigated (if necessary) by the Medicines Compliance team. A link to the General Report can be found at: <https://www.health.qld.gov.au/medicines-poisons-forms/general-report>.

Furthermore, if your members have particular concerns about the practice, conduct or health of a health practitioner practising in Queensland, it is recommended that they consider whether they should make a notification to the Queensland Office of the Health Ombudsman (OHO). Further information regarding OHO notifications can be found here: <https://www.oho.qld.gov.au/for-providers/make-a-notification>.

As you will also be aware, the Therapeutic Goods Administration (TGA), Australian Government Department of Health, Disability and Ageing is currently undertaking public consultation to review the safety and regulatory oversight of unapproved medicinal cannabis products. I would encourage you to make a submission to the TGA.

The TGA's consultation paper and details on how to make a submission are available on the TGA website: <https://www.tga.gov.au/resources/consultation/consultation-reviewing-safety-and-regulatory-oversight-unapproved-medicinal-cannabis-products>.

The consultation period closes on 7 October 2025.

Thank you again for your letter to support the Minister at this meeting.

Yours sincerely



**Dr David Walker**  
Acting Chief Medical Officer  
Health Workforce Division

18 / 09 / 2025